Laboratory Valuation
| LH Stock | USD 278.11 11.78 4.06% |
At this time, the firm appears to be undervalued. Laboratory secures a last-minute Real Value of $298.19 per share. The latest price of the firm is $278.11. Our model forecasts the value of Laboratory from analyzing the firm fundamentals such as Profit Margin of 0.06 %, return on equity of 0.1, and Current Valuation of 29.96 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Laboratory's valuation include:
Undervalued
Today
Please note that Laboratory's price fluctuation is very steady at this time. Calculation of the real value of Laboratory is based on 3 months time horizon. Increasing Laboratory's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Laboratory is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Laboratory Stock. However, Laboratory's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 278.11 | Real 298.19 | Target 300.18 | Hype 278.66 |
The intrinsic value of Laboratory's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Laboratory's stock price.
Estimating the potential upside or downside of Laboratory of helps investors to forecast how Laboratory stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Laboratory more accurately as focusing exclusively on Laboratory's fundamentals will not take into account other important factors: When choosing an evaluation method for Laboratory, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Laboratory Cash |
|
Laboratory Total Value Analysis
Laboratory of is now forecasted to have takeover value of 29.96 B with market capitalization of 24.09 B, debt of 7.27 B, and cash on hands of 1.52 B. Please note that takeover value may be misleading and is a subject to accounting mistakes. We encourage investors to methodically examine all of the Laboratory fundamentals before making investment evaluation based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.96 B | 24.09 B | 7.27 B | 1.52 B |
Laboratory Investor Information
About 99.0% of the company shares are owned by institutional investors. The book value of Laboratory was now reported as 104.78. The company has Price/Earnings To Growth (PEG) ratio of 2.12. Laboratory recorded earning per share (EPS) of 10.2. The entity last dividend was issued on the 27th of February 2026. The firm had 1164:1000 split on the 3rd of July 2023. Based on the key measurements obtained from Laboratory's financial statements, Laboratory of is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in March.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.17 | 0.0961 |
|
| |||||
| Total Cash From Operating Activities | 1.9 B | 1.8 B |
|
| |||||
| Operating Income | 814 M | 1.2 B |
|
|
Laboratory Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Laboratory has an asset utilization ratio of 70.78 percent. This signifies that the Company is making $0.71 for each dollar of assets. An increasing asset utilization means that Laboratory of is more efficient with each dollar of assets it utilizes for everyday operations.Laboratory Profitability Analysis
Based on the key profitability measurements obtained from Laboratory's financial statements, Laboratory of is performing exceptionally good at this time. It has a great probability to showcase excellent profitability results in March. Profitability indicators assess Laboratory's ability to earn profits and add value for shareholders.Net Income | First Reported 1988-03-31 | Previous Quarter 237.9 M | Current Value 261.1 M | Quarterly Volatility 160.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.42 | 0.32 |
|
| |||||
| Net Profit Margin | 0.0697 | 0.0516 |
|
| |||||
| Operating Profit Margin | 0.17 | 0.0961 |
|
| |||||
| Pretax Profit Margin | 0.14 | 0.0848 |
|
| |||||
| Return On Assets | 0.0876 | 0.0467 |
|
| |||||
| Return On Equity | 0.18 | 0.11 |
|
|
For Laboratory profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Laboratory to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Laboratory utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Laboratory's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Laboratory over time as well as its relative position and ranking within its peers.
Laboratory Earnings per Share Projection vs Actual
The next projected EPS of Laboratory is estimated to be 4.1045 with future projections ranging from a low of 3.98 to a high of 4.25. Laboratory's most recent 12-month trailing earnings per share (EPS TTM) is at 10.2. Please be aware that the consensus of earnings estimates for Laboratory of is based on EPS before non-recurring items and includes expenses related to employee stock options.Laboratory Earnings Estimation Breakdown
The calculation of Laboratory's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Laboratory is estimated to be 4.1045 with the future projection ranging from a low of 3.98 to a high of 4.25. Please be aware that this consensus of annual earnings estimates for Laboratory of is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
3.98 Lowest | Expected EPS | 4.25 Highest |
Laboratory Earnings Projection Consensus
Suppose the current estimates of Laboratory's value are higher than the current market price of the Laboratory stock. In this case, investors may conclude that Laboratory is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Laboratory's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 19 | 93.51% | 0.0 | 4.1045 | 10.2 |
Laboratory Ownership Allocation
Laboratory maintains a total of 82.9 Million outstanding shares. The majority of Laboratory outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Laboratory of to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Laboratory. Please pay attention to any change in the institutional holdings of Laboratory as this could imply that something significant has changed or is about to change at the company. On February 3, 2026, Representative April Delaney of US Congress acquired under $15k worth of Laboratory's common stock.Laboratory Profitability Analysis
The company generated the yearly revenue of 13.01 B. Reported Net Income was 746 M with gross profit of 3.92 B.Laboratory Past Distributions to stockholders
About Laboratory Valuation
An absolute valuation paradigm, as applied to Laboratory Stock, attempts to find the value of Laboratory based on its fundamental and basic technical indicators. By analyzing Laboratory's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Laboratory's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Laboratory. We calculate exposure to Laboratory's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Laboratory's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 4.2 B | 4.4 B | |
| Pretax Profit Margin | 0.08 | 0.14 | |
| Operating Profit Margin | 0.10 | 0.17 | |
| Net Profit Margin | 0.05 | 0.07 | |
| Gross Profit Margin | 0.32 | 0.42 |
A single share of Laboratory represents a small ownership stake in the entity. As a stockholder of Laboratory, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Laboratory Dividends Analysis For Valuation
As of now, Laboratory's Dividend Payout Ratio is decreasing as compared to previous years. The Laboratory's current Dividend Paid And Capex Coverage Ratio is estimated to increase to 2.92, while Dividends Paid is projected to decrease to under 265.6 M. . The Laboratory's current Retained Earnings is estimated to increase to about 10 B. The Laboratory's current Retained Earnings Total Equity is estimated to increase to about 12.6 B
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 279.6 M | 265.6 M | |
| Dividend Yield | 0.01 | 0.01 | |
| Dividend Payout Ratio | 0.29 | 0.31 | |
| Dividend Paid And Capex Coverage Ratio | 1.95 | 2.92 |
There are various types of dividends Laboratory can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Laboratory shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Laboratory of directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Laboratory pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Laboratory by the value of the dividends paid out.
Laboratory Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 84.4 M | |
| Quarterly Earnings Growth Y O Y | 0.56 | |
| Forward Price Earnings | 16.3666 |
Laboratory Current Valuation Indicators
Valuation refers to the process of determining the present value of Laboratory of and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Laboratory we look at many different elements of the entity such as Laboratory's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Laboratory, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Laboratory's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Laboratory's worth.Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |